Nephros (NASDAQ: NEPH) shares updated 2026 corporate presentation with market

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Nephros, Inc. furnished a current report to highlight that it has posted an updated 2026 Corporate Presentation on its corporate website. The presentation is provided as Exhibit 99.1 and is being shared as a Regulation FD disclosure, meaning it is intended to give the market broadly equal access to the same information.

The company notes that the presentation and related disclosure are considered "furnished" rather than "filed" under securities laws, which affects how they may be used in securities law liability and future SEC filings. The report is signed on behalf of Nephros by Chief Financial Officer Judy Krandel.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

03/27/2026 - 04:00 PM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 27, 2026

NEPHROS, INC.

(Exact name of Registrant as Specified in its Charter)

Delaware

001-32288

13-3971809

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

380 Lackawanna Place, South Orange, New Jersey 07079
(Address of principal executive offices, including ZIP code)

(201) 343-5202
(Registrant’s telephone number, including area code)

n/a
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.001 par value		NEPH		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On March 27, 2026, Nephros, Inc. (the “Company”) posted an updated 2026 Corporate Presentation on its corporate website. A copy of this presentation is furnished herewith as Exhibit 99.1.

Pursuant to the rules and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein and in this Item 7.01 have been furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing regardless of any general incorporation language.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Nephros, Inc. 2026 Corporate Presentation.
104		Cover Page Interactive Data File (embedded M2 Compliance within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

	Nephros, Inc.

Dated: March 27, 2026	By:	/s/ Judy Krandel
		Judy Krandel
		Chief Financial Officer

Exhibit 99.1

Source: View Original Filing on SEC EDGAR

FAQ

What did Nephros (NEPH) announce in its latest 8-K filing?

Nephros reported that it posted an updated 2026 Corporate Presentation on its corporate website. The presentation is furnished as Exhibit 99.1 under Regulation FD, giving investors access to the same information at the same time.

How is Nephros (NEPH) 2026 Corporate Presentation provided to investors?

The 2026 Corporate Presentation is made available on Nephros’ corporate website and furnished as Exhibit 99.1. Including it in the 8-K helps ensure broad, simultaneous disclosure of the information contained in the presentation.

Is Nephros’ 2026 Corporate Presentation considered filed with the SEC?

No. Nephros states that the presentation and related disclosure are furnished, not filed, under the Exchange Act. This distinction limits how the material is treated for Section 18 liability and future incorporation by reference.

Which exhibit in the Nephros (NEPH) 8-K contains the 2026 Corporate Presentation?

Exhibit 99.1 to the 8-K contains the Nephros, Inc. 2026 Corporate Presentation. The company also includes Exhibit 104, which is the cover page interactive data file embedded within the Inline XBRL document.

Who signed the March 27, 2026 Nephros (NEPH) 8-K report?

The report was signed on behalf of Nephros, Inc. by Chief Financial Officer Judy Krandel. Her signature indicates the company’s authorization and acknowledgment of the contents of this current report on Form 8-K.

On which exchange is Nephros (NEPH) common stock listed?

Nephros’ common stock, with a par value of $0.001 and trading symbol NEPH, is listed on The Nasdaq Stock Market LLC. This listing information is included in the securities section of the current report.

Filing Exhibits & Attachments

36 documents